AI brings savings to clinical trials: study

A Tufts Center for the Study of Drug Development analysis found AI agents can accelerate clinical development of cancer drugs by approximately 10 weeks and reduce direct operating costs by as much as $5.6 million in late-stage trials. An experimental treatment with 50 active uses could see net benefits of up to $565 million.